Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:21:05 EDT Sat 27 Apr 2024
Enter Symbol
or Name
USA
CA



Q:BIIB - BIOGEN INC - http://www.biogenidec.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BIIB - Q0.1190.68·208.591.5208.90+6.443.21,893.9392,67428,546201.22  210.83  199.10319.76  189.4419:51:57Mar 3115 min RT 2¢

Recent Trades - Last 10 of 28546
Time ETExPriceChangeVolume
19:51:57Q208.506.042
18:17:10Q208.285.8210
18:13:42Q207.995.531
17:56:41Q207.5045.04410
17:53:43Q205.983.521
16:54:50Q208.906.4412,243
16:48:10Q208.005.541
16:42:15Q200.00-2.461
16:19:33Q208.79566.33561,494
16:15:11Q209.657.199

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-31 19:30U:BIIBNews ReleaseEisai Completes Submission of LEQEMBI(TM) (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
2024-03-06 07:31U:BIIBNews ReleaseNew Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA(TM) (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
2024-03-04 16:16U:BIIBNews ReleaseBiogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD(TM)) 2024 Annual Meeting
2024-02-23 07:00U:BIIBNews ReleaseBiogen's QALSODY(TM) (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
2024-02-12 16:06U:BIIBNews ReleaseBiogen Received European Commission Approval for SKYCLARYS ‚ ® (omaveloxolone), the First Therapy to Treat Friedreich ¢ € ™s Ataxia
2024-01-31 07:30U:BIIBNews ReleaseBiogen to Realign Resources for Alzheimer's Disease Franchise
2023-12-19 07:30U:BIIBNews ReleaseCentralized Marketing Authorizations of Generic Versions of TECFIDERA ‚ ® are Revoked by the European Commission
2023-12-15 09:05U:BIIBNews ReleaseCHMP Issues Positive Opinion for Biogen ¢ € ™s SKYCLARYS ‚ ® (omaveloxolone), the First Therapy to Treat Friedreich ¢ € ™s Ataxia, a Rare Neurodegenerative Disease
2023-12-14 06:30U:BIIBNews ReleaseZURZUVAE ¢ „ ¢ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
2023-11-06 07:30U:BIIBNews ReleaseBiogen Appoints Monish Patolawala to its Board of Directors
2023-10-25 17:26U:BIIBNews ReleaseEisai Presents New LEQEMBI ‚ ® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer ¢ € ™s Disease From Additional Analyses of Clarity AD at The Clinical Trials
2023-10-25 17:25U:BIIBNews ReleaseEISAI PRESENTS NEW LEQEMBI ‚ ® (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON AL
2023-10-25 10:51U:BIIBNews ReleaseNew Data from Biogen ¢ € ™s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer ¢ € ™s Disease
2023-10-24 09:30U:BIIBNews ReleaseLEQEMBI ‚ ® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023
2023-10-19 07:30U:BIIBNews ReleaseBiogen to Present New Data at the Clinical Trials on Alzheimer ¢ € ™s Disease (CTAD) 2023 Meeting
2023-09-29 16:06U:BIIBNews ReleaseFDA Approves Biogen ¢ € ™s TOFIDENCE ¢ „ ¢ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA ‚ ®
2023-09-26 09:00U:BIIBNews ReleaseBiogen Completes Acquisition of Reata Pharmaceuticals
2023-09-25 01:03U:BIIBNews ReleaseLEQEMBI ‚ ® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer ¢ € ™s Disease in Japan
2023-09-06 07:30U:BIIBNews ReleaseBiogen Appoints Jane Grogan as Head of Research